OncoMatch

OncoMatch/Clinical Trials/NCT06727773

Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer

Is NCT06727773 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Memantine for breast cancer.

Phase 2RecruitingUNC Lineberger Comprehensive Cancer CenterNCT06727773Data as of Jun 2026

Treatment: MemantineThis randomized, placebo-controlled trial aims to assess the feasibility, acceptability, and preliminary efficacy of memantine and the University of Carolina (UNC)'s Get Real \& Heel cancer exercise program (MEM+EX) in addressing cancer-related cognitive impairment (CRCI) and underlying CRCI biomarkers. Ninety stage I-III breast cancer patients with mild cognitive difficulties during chemotherapy will be randomized into three groups: MEM+EX, memantine, or placebo. The study will evaluate recruitment, retention, adherence, acceptability, cognitive function, brain-derived neurotrophic factor (BDNF), inflammatory markers, and frailty at multiple time points.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

Memantine

Cancer type

Breast Carcinoma

Disease stage

Required: Stage I, II, III

Demographics

Female only

Prior therapy

Min 1 prior line

Must have received: chemotherapy — neoadjuvant or adjuvant

Completed at least 1 cycle of standard-of-care neoadjuvant or adjuvant chemotherapy

Cannot have received: chemotherapy

Exception: prior to the current regimen

Previous chemotherapy (prior to the current regimen)

Lab requirements

Kidney function

CrCl ≤ 5mL/min [excluded]

Cardiac function

Myocardial infarction in the last 6 months [excluded]

Myocardial infarction in the last 6 months; CrCl ≤ 5mL/min

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill · Chapel Hill, North Carolina

Showing up to 5 US sites.

See all sites on ClinicalTrials.gov →

Frequently asked questions

Is NCT06727773 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior chemotherapy disqualifies patients from enrollment.

What disease stage is eligible?

Stage I or II or III is required.

Is this trial open to male patients?

No. This trial enrolls female patients only.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify